SCHEMBL5653936

SCHEMBL5653936

O=C(O)c1ccc(-c2nc3cc(Cl)c(Cl)cc3[nH]2)c(O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 4/20 0.55
PRSS12 P56730 3/20 0.55
RHEB Q15382 2/20 0.53
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
KMT2A Q03164 1/20 0.52
PRKAG1 P54619 1/20 0.51
PRKAA2 P54646 1/20 0.51
PRKAB1 Q9Y478 1/20 0.51
MAPT P10636 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
TP53 P04637 1/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GCGR P47871 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
GRIN2D O15399 1/20 0.49
GRIN3B O60391 1/20 0.49
LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650767 0.84 RHEB (0.57) CHEK2PRSS12RHEBPRKAG1PRKAA2
SCHEMBL2714424 0.82 RHEB (0.71) CHEK2PRSS12RHEBKMT2ANR4A2
SCHEMBL14514690 0.81 NPC1 (0.53) CHEK2PRSS12RHEBMEN1NPC1
Hydrochloric Acid SCHEMBL5650486 0.80 NPC1 (0.52) CHEK2PRSS12RHEBMEN1NPC1
SCHEMBL15455614 0.80 AMY1A (0.53) CHEK2MEN1NPC1RAB9AKMT2A
SCHEMBL3183271 0.77 CHEK2 (0.68) CHEK2MAPTTDP1POLBHDAC6
SCHEMBL3169464 0.77 CHEK2 (0.77) CHEK2MAPTTDP1TP53POLB
SCHEMBL31429585 0.77 F2 (0.55) CHEK2MEN1NPC1RAB9AKMT2A
SCHEMBL12471073 0.77 F2 (0.55) CHEK2MEN1NPC1RAB9AKMT2A
SCHEMBL5952668 0.76 CHEK1 (0.69) CHEK2RHEBPRKAG1PRKAA2PRKAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed
EP-1187813-A1 AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS SMITHKLINE BEECHAM PLC (GB) 2002-03-20 EP disclosed
WO-2001000587-A1 AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS SMITHKLINE BEECHAM P.L.C. (GB) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 CHEK2 4002/4885PRSS12 979/4885RHEB 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.